Cerebral cavernous malformations (CCMs) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. They cause seizures and cerebral hemorrhages, which can result in focal neurological deficits. Three CCM loci have been mapped, and loss-of-function mutations were identified in the KRIT1 (CCM1) and MGC4607 (CCM2) genes. We report herein the identification of PDCD10 (programmed cell death 10) as the CCM3 gene. The CCM3 locus has been previously mapped to 3q26-27 within a 22-cM interval that is bracketed by D3S1763 and D3S1262. We hypothesized that genomic deletions might occur at the CCM3 locus, as reported previously to occur at the CCM2 locus. Through high-density microsatellite genotyping of 20 families, we identified, in one family, null alleles that resulted from a deletion within a 4-Mb interval flanked by markers D3S3668 and D3S1614. This de novo deletion encompassed D3S1763, which strongly suggests that the CCM3 gene lies within a 970-kb region bracketed by D3S1763 and D3S1614. Six additional distinct deleterious mutations within PDCD10, one of the five known genes mapped within this interval, were identified in seven families. Three of these mutations were nonsense mutations, and two led to an aberrant splicing of exon 9, with a frameshift and a longer open reading frame within exon 10. The last of the six mutations led to an aberrant splicing of exon 5, without frameshift. Three of these mutations occurred de novo. All of them cosegregated with the disease in the families and were not observed in 200 control chromosomes. PDCD10, also called "TFAR15," had been initially identified through a screening for genes differentially expressed during the induction of apoptosis in the TF-1 premyeloid cell line. It is highly conserved in both vertebrates and invertebrates. Its implication in cerebral cavernous malformations strongly suggests that it is a new player in vascular morphogenesis and/or remodeling.
Introduction
Cerebral cavernous malformations (CCMs [MIM 116860] ) are vascular malformations, mostly located within the CNS. They are characterized by abnormally enlarged capillary cavities without intervening brain parenchyma (Russel and Rubinstein 1989) . The most common symptoms are seizures and neurological deficits that result from focal hemorrhages (Rigamonti et al. 1988; Labauge et al. 1998) . The prevalence of this condition has been estimated to be 0.1%-0.5% (Otten et al. 1989) .
Cavernous angiomas can occur in a sporadic or au-tosomal dominant inherited form. The proportion of familial cases has been estimated as high as 50% in Hispanic American patients with CCMs (Rigamonti et al. 1988 ) and close to 10%-20% in white patients (E. Tournier-Lasserve, unpublished data). Familial cases are characterized by the presence of multiple lesions, whereas sporadic cases usually harbor only one CCM lesion (Rigamonti et al. 1988; Labauge et al. 1998) . Clinical penetrance is incomplete, and it has been suggested that it might depend on the CCM locus involved (Craig et al. 1998; Denier et al. 2004) . Three CCM loci have been previously mapped to 7q (CCM1), 7p (CCM2), and 3q (CCM3), with 40% of kindreds with CCMs being linked to CCM1, 20% linked to CCM2, and 40% linked to CCM3 (Dubovsky et al. 1995; Craig et al. 1998) . Two CCM genes have been identified so far-KRIT1 (CCM1) and MGC4607 (CCM2)-and the nature of their mutations in patients with CCMs strongly suggests a loss of function in both cases (Laberge-le Couteulx et al. 1999; Sahoo et al. 1999; Liquori et al. 2003; Denier et al. 2004) .
Krit1 was initially identified as a rap1A-interacting protein (Serebriiskii et al. 1997 ). Subsequently, its N-terminal part, which contains an NPXY motif, was shown to strongly interact with icap1a, a phosphoprotein that binds to the intracytoplasmic tail of integrin b1 (Zhang et al. 2001; Zawistowski et al. 2002) . Given the multiple roles of integrins in processes such as cell differentiation, proliferation, and/or apoptosis, as well as their implications in angiogenesis, these data suggest that Krit1 might play a role in integrin signaling pathways during vessel morphogenesis. Krit1 transcripts have been detected in neural and epithelial cells during development, and the Krit1 protein has been detected in various cells, including neurons, glial cells, and endothelial cells, and was reported to be associated with microtubules (Denier et al. 2002; Gunel et al. 2002; Guzeloglu-Kayisli et al. 2004) . A recent invalidation of this gene in the mouse has shown that Krit1 is not required for vasculogenesis but is needed for arterial morphogenesis and identity (Whitehead et al. 2004 ). However, the early E11 embryonic lethality observed in these invalidated embryos hampered the investigations needed to explore the mechanisms that lead from Krit1 loss to CCM lesions. With regard to MGC4607, nothing is known about the function of this protein, except that it contains a phosphotyrosin-binding domain and is involved in osmolarity sensing (Uhlik et al. 2003) .
The CCM3 gene had been previously mapped to a 22-cM interval bracketed by D3S1763 and D3S1262. We did not have access to any large family for which linkage analysis could be performed to reduce the size of this genetic interval. In the absence of any strong candidate gene within this large interval, we chose to use another strategy to reduce the size of the region of interest. We hypothesized that deletions might be involved in this condition, as has been reported elsewhere for other hamartomatous conditions, such as tuberous sclerosis, neurofibromatosis, or CCM2 cavernous angiomas (Viskochil et al. 1990; European Chromosome 16 Tuberous Sclerosis Consortium 1993; Trofatter et al. 1993; Denier et al. 2004 ). We performed a high-density microsatellite genotyping of this 22-cM interval to search for putative null alleles in 20 small but potentially informative families with CCMs. In one patient, we identified a de novo deletion within a 4-Mb interval flanked by markers D3S3668 and D3S1614. This deletion encompassed D3S1763, the centromeric boundary of the CCM3 interval, which strongly suggests that the CCM3 gene lies within a 970-kb interval bracketed by D3S1763 and D3S1614. In seven families, we identified deleterious mutations within the programmed cell death 10 gene (PDCD10), one of the five known genes that have been mapped to this interval. These data establish PDCD10, a gene highly conserved in vertebrates and invertebrates, as a new player in vessel development and/or maturation.
Material and Methods

Patients and Families
Twenty unrelated families were enrolled in this study, on the basis of three criteria: (1) each proband had at least one affected relative and/or had multiple cerebral cavernous angiomas; (2) the families of these probands were potentially informative for a study designed to detect genomic deletions, on the basis of the identification of microsatellite null alleles; and (3) molecular screening for KRIT1 and MGC4607 point mutations was negative. CCM diagnosis was based on cerebral magnetic resonance imaging (MRI) features and/or pathological analysis. We considered as "affected" all individuals who showed cavernous angiomas on cerebral MRI, whatever their clinical status. We considered as "healthy" all individuals with normal MRI results. Those who did not undergo MRI were classified as "unknown" ( fig. 1 ).
DNA and RNA Extraction
Genomic DNA from probands and consenting relatives was extracted from peripheral blood by use of standard procedures. Genomic DNA from 100 unrelated, healthy, white French individuals was available as a control group. Total RNA was extracted from lymphoblastoid Epstein-Barr virus (EBV) cell lines for 17 of the 20 probands (lymphoblastoid cell lines were not available for probands C064, C077, and C114), and cDNA was prepared in accordance with standard procedures.
Genetic Markers
For the initial microsatellite screening, we used a panel of 18 microsatellite markers that spanned the CCM3 interval (D3S1763-D3S1262) and the immediate centromeric and telomeric regions located on both sides of this interval. The average distance between the markers was !1 Mb. This panel included markers D3S1580, D3S3686, D3S1262, D3S3592, D3S3583, D3S3609, D3S3730, D3S3715, D3S3676, D3S3520, D3S3725, D3S3053, D3S1574, D3S1282, D3S1614, D3S3622, D3S1264 , and D3S3673 (in qterrcen orientation) (figs. 2 and 3A).
Additional markers were used to define the boundaries of the de novo deletion identified in family C052, including D3S3682, D3S3668, D3S1268, D3S3689, and new CA-repeat markers identified through screening for dinucleotide tracks of ad hoc genomic sequences that spanned the D3S3668-D3S1614 interval. Seven new CA-repeat markers were identified and were designated CA-AC092965a and CA-AC092965b (BAC 
PDCD10 Mutation Screening
Genomic DNA of all probands was amplified using 10 sets of primers designed to amplify each of the coding exons (exons 4-10), the 5 noncoding exons, and the flanking splice sites and was analyzed by direct sequencing on an ABI 3100 (PE Applied Biosystems) (table 1) . cDNA from all probands (except probands C064, C077, and C114, from whom no cDNA was available) was amplified using a set of two primers to amplify an 802-bp fragment that spanned exons 4-10 (table 1) . Amplicons were checked on agarose gels and were sequenced on an ABI 3100 (PE Applied Biosystems).
Multiple-Tissue Northern (MTN) Blot
An 802-bp cDNA probe that contained exons 4-10 was generated from a lymphoblastoid EBV cell line derived from a normal healthy control (fragment 4-10 [table 1]) and was cloned in the pGEM-T Easy Vector System (Promega). The probe sequence was identical to the reported human sequence. One hundred nanograms of the full-length cDNA fragment were radiolabeled with [ 32 P]-dCTP and were used to hybridize a human adult MTN blot (Human 12-lane MTN Blot [Clontech] ) in ExpressHyb solution (Clontech) at 1-2 # 10 6 cpm/ml, in accordance with manufacturer instructions. Kodak film was exposed to the blot at Ϫ80ЊC for 17 h for PDCD10 and for 6 h for the control b-actin probe (Clontech).
Results
De Novo Deletion in Family C052
None of the families available in this study was large enough to allow us to reduce the size of the CCM3 interval through genetic linkage analysis and identification of recombinants. We hypothesized that deletions might be involved in CCM, so we searched with 18 microsatellite markers for putative null alleles in 20 unrelated families. We did not detect any abnormality, except in family C052, in whom apparent non-Mendelian inheritance was observed for three contiguous markers-D3S3673, D3S1264, and D3S3622-located at the centromeric boundary of the CCM3 interval ( fig. 2) . Patient III1 in that family appeared homozygous and failed to inherit an allele from her heterozygous unaffected father for all three markers. The same family did not exhibit incompatible genotypes with other markers, which thus eliminated inaccurate paternity information and sampling error as sources of incompatibility. Individual III1 was heterozygous at D3S1614 and D3S3668 and compatible with her father. Analysis of family C052 with the use of additional microsatellites located centromeric to D3S1614 detected null alleles at D3S3682 and CA-AC092965b ( fig. 3) , whereas genotypes of individual III1 for other centromeric markers, including AC072046, AC104629, AC108675, AC013458, and D3S3668, were heterozygous and compatible with the family structure. These data were consistent with a deletion of a maximum size of 1.9 Mb within an interval flanked by markers D3S1614 (telomeric boundary) and CA-072046 (centromeric boundary). Its minimum size was estimated at 1.1 Mb. This deletion encompassed D3S1763, the previously defined CCM3 centromeric
Figure 3
A, Genetic map of the CCM3 locus. The two markers that bracketed the previously published CCM3 interval-D3S1763 and D3S1262-are indicated in bold. Some of the microsatellite markers used to screen families for putative null alleles are shown. B, CCM3 deletion in pedigree C052. Microsatellites used to identify and refine the deletion in the proband from family C052 are shown. Dots denote markers for which apparent non-Mendelian inheritance was observed in the C052 proband. Vertical bars denote heterozygosities at given markers.
A de novo deletion that encompasses D3S1763 was detected in the C052 proband. The novel critical interval, now bracketed by D3S1763 and D3S1614, is blackened. C, Genes mapped within the novel CCM3 interval. The five genes identified within this interval are schematized as arrows. boundary, which strongly suggested that the critical interval that contained the gene spanned 970 kb and was bracketed by D3S1763 and D3S1614.
PDCD10 Point Mutations
Five known or putative genes have been mapped within this critical interval: FLJ33620, PDCD10, SERPINI1, GOLPH4, and LOC389174 (see the NCBI Web site). We designed sets of primers to amplify genomic DNA and cDNA for each of those genes. On the basis of its putative role in apoptosis, PDCD10 was selected as the first gene for screening (Wang et al. 1999) .
Genomic DNA sequence analysis identified five deleterious mutations in six of the probands, including three direct nonsense mutations and two splice-site mutations that lead to a frameshift. The probands from families C030 and C077 harbored the same mutation (nt 586CrT, stop codon at codon 196); haplotype analysis did not favor any founder effect in these two families (data not shown). The C031 proband had a mutation in exon 7 (nt 385CrT, stop codon at codon 129), and the C055 proband had a mutation in exon 5 (nt 103 CrT, stop codon at codon 35). The C107 proband had a splice-site mutation in intron 8 (nt 475-1GrA). A deletion of one of the two AAGT short repeats located between exon 9 and IVS9 was detected in the C044 proband (table 2; fig. 4A and 4B ). Agarose gel electrophoresis of amplified cDNA revealed abnormal transcripts in the C107 and C044 probands. Sequence analysis of the cDNA of these probands showed an abnormal splicing of exon 9, leading to a frameshift and a change in the position of the stop codon (TGA, nt 637-639/ TGA, nt 681-683).
In addition, cDNA analysis showed an abnormal transcript in which exon 5 was abnormally spliced in the C043 proband. No genomic mutation was detected at consensus splice sites in this patient. This abnormal transcript was detected neither in any of our controls nor in the 1150 ESTs reported so far in databases, which strongly suggests that this abnormal transcript is pathogenic and might be due to an as-yet undetected intronic mutation that affects splicing or to a deletion of the genomic region that encompasses exon 5.
Combined haplotype and mutation screening of relatives of these probands showed that three of these mutations occurred de novo in the probands of pedigrees C044, C052, and C107. Within pedigrees C030, C031, C043, C055, and C077, the mutation cosegregated with the affected phenotype. None of the identified mutations was detected in the panel of 200 control chromosomes.
In summary, a total of eight different mutations, including one large deletion, have been observed in this panel of 20 families with CCMs. Interestingly, we did not detect any exonic polymorphism of this gene in the 20 probands.
Structure of the PDCD10 Gene, cDNA, and Protein PDCD10 cDNA (alias, "TFAR15") was initially cloned on the basis of its up-regulated expression in a human myeloid cell line, TF-1, in which apoptosis has been induced by deprivation of granulocyte macrophage colonystimulating factor (Wang et al. 1999) . Its cDNA and genomic structures have been reported in several genome databases with 1150 reported ESTs. It extends 150 kb and includes seven coding exons and three 5 noncoding exons. Three alternative transcripts that differ only in their 5 UTRs have been identified for this gene (GenBank accession numbers NM_007217, NM_145859, and NM_145860). The ATG initiator codon is located in the fourth exon. 
PDCD10 mRNA Expression
Northern blot analysis showed ubiquitous expression, in agreement with the expression pattern that can be deduced from the multiple PDCD10 ESTs reported in the dBEST database. A band of ∼1.35 kb was detected in all tissues tested, although at a different level ( fig. 5) , consistent with the 1.4-kb, 1.3-kb, and 1.2-kb sizes of the three reported PDCD10 transcripts.
Discussion
We have identified PDCD10 as the gene that causes CCM in families with CCM3, on the basis of the identification of seven distinct mutations in eight unrelated families. The nature of some of these mutations, particularly the deletion of the whole gene observed in family C052, strongly suggests that one of the mechanisms that leads to cavernous angiomas might be PDCD10 haploinsufficiency.
We detected a mutation in 8 of the 20 families in our study. CCMs are genetically heterogeneous, and multilocus linkage data suggested that 40% of families with CCMs are linked to the CCM3 locus (Craig et al. 1998) . Since the 20 families screened in this study were included on the basis of a negative KRIT1 (CCM1) and MGC4607 (CCM2) mutation screening, a higher proportion of families with a PDCD10 mutation would have been expected. Several hypotheses can be raised to explain this discrepancy. Some of these families might have a genomic deletion within either PDCD10, KRIT1, or MGC4607, which would not have been detected by the exon-by-exon sequencing approach used to screen those three genes. Another hypothesis could be the existence of additional, as-yet unidentified exons within PDCD10. Although this possibility cannot be excluded, there is no discrepancy between the size of the reported cDNA and that of the transcript seen in the northern blot. A third possibility is somatic mosaicism of a de novo mutation in any of the three CCM genes, which would be present at a low frequency in leukocyte DNA, particularly in the families in whom the proband is the only affected case. As has been reported elsewhere with regard to other hamartomatous conditions, this somatic mosaicism may render quite difficult the identification of the deleterious mutation (Verhoef et al. 1999 ). Finally, we cannot exclude the possibility of the existence of a fourth CCM gene that either was missed in the multilocus linkage analysis or is located in close proximity to one of the three CCM genes identified so far.
The identification of PDCD10 as the CCM3 gene raises the question of its cellular function and its specific role in angiogenesis and/or remodeling of cerebral vessels. PDCD10/TFAR15 was initially identified as a gene upregulated in the TF-1 premyeloid cell line after growthfactor deprivation and apoptosis induction (Wang et al. 1999) . This gene was shown recently to be up-regulated, in a study designed to identify apoptosis-related genes in a fibroblast cell line exposed to specific apoptosis inducers, such as staurosporine, cycloheximide, and TNF-a (Busch et al. 2004) . These preliminary data suggest that this gene, which is highly conserved from nematode to human, might play a role in apoptotic pathways. Inhibition of the nematode PDCD10 ortholog, 2K896, leads to embryonic lethality in 40% of the embryos and a dumpy phenotype in postembryonic viable embryos (Kamath et al. 2003) . However, the pathways and mechanisms that lead to these phenotypes are unknown. In summary, these data establish PDCD10, a protein that has been related to apoptosis, as a new player in vessel development and/or maturation. The putative role of this protein in an apoptotic pathway that might be involved in angiogenesis and the putative link of such a pathway with either KRIT1 and/or MGC4607 remain to be investigated.
